Enveda

Enveda

Natural-product drug discovery platform leveraging ML

Overview

Enveda Biosciences uses machine learning, metabolomics, and robotics to explore the largely untapped natural world for drug discovery. Its main asset is a proprietary high-throughput platform that runs many experiments to generate a comprehensive dataset of small molecules, including their chemical structures, biological activity, and how they distribute in organs. This data helps identify potential drug leads quickly and supports partnerships with healthcare and pharmaceutical companies through collaborations and licensing of discoveries. Unlike many rivals, Enveda focuses on expanding knowledge of natural product chemistry beyond the small portion already known, aiming to accelerate the pace of drug discovery by systematically exploring natural chemical space and building a pipeline for its partners.

About Enveda

Simplify's Rating
Why Enveda is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Robotics & Automation

Biotechnology

Healthcare

Company Size

201-500

Company Stage

Series D

Total Funding

$534.8M

Headquarters

Boulder, Colorado

Founded

2019

Get referred to Enveda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Three clinical candidates and one clinical program improve investability.
  • Partnerships with large pharma can generate upfront and royalty revenue.
  • Christopher K. Porter and Mikael Dolsten add clinical and commercial credibility.

What critics are saying

  • Lead-program failure would undermine the platform's human-efficacy thesis.
  • Clinical scaling errors can delay readouts and accelerate cash burn.
  • Natural compounds remain hard to patent, reproducing, and de-risk for partners.

What makes Enveda unique

  • AI-driven natural-product mining targets unexplored chemical space.
  • Integrated metabolomics, mass spectrometry, and robotics accelerate candidate discovery.
  • Over one million natural compounds strengthen Enveda's proprietary data moat.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$534.8M

Above

Industry Average

Funded Over

10 Rounds

Series D funding is typically for companies that are already well-established but need more funding to continue their growth. This round is often used to stabilize the company or prepare for an IPO.
Series D Funding Comparison
Above Average

Industry standards

$77M
$70M
Twilio
$80M
Handshake
$100M
Affirm
$150M
Enveda

Benefits

Traditional or Roth 401k matching of 4% (100% of your contributions up to 4% of your annual compensation)

Medical, dental and vision insurance. 100% coverage of employee premiums and 33% coverage of dependents

Unlimited paid time off

Flexible work hours and paid parental leave

Company-wide weeklong break to recharge in addition to 8 observed holidays

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

1%
Business Wire
Sep 5th, 2025
Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors

Enveda raises $150M Series D, reaches unicorn status, enrolls first patient in clinical trials, and adds former Pfizer CSO Mikael Dolsten to board.

Endpoints News
Sep 4th, 2025
Enveda Biosciences Secures $150M Funding

Enveda Biosciences, a Colorado biotech, has secured an additional $150 million for its I&I drug and a wide-ranging pipeline of preclinical assets. The company has grown from an initial $50k "pre, pre-seed" investment to $517 million in total funding, achieving unicorn status.

BioPharma Dive
Sep 4th, 2025
Enveda Biosciences raises $150M for drugs

Enveda Biosciences raised $150 million in Series D funding, doubling its venture capital intake this year. The round was led by Premji Invest and included investors like Kinnevik and Lux Capital. Enveda has begun Phase 1b trials for its lead drug candidate in atopic dermatitis and plans to enter more drugs into human trials soon. The company aims to file investigational new drug applications for other programs over the next year.

AgFunderNews
May 20th, 2025
Corteva: Ai Can Transform Crop Protection To Replace ‘Randomness And Chance’ With ‘Prediction, Specificity And Design’

AI is helping Corteva Agriscience dramatically accelerate the development of new crop protection products by modeling proteins and molecules with “unprecedented speed and accuracy,” an exec told a congressional subcommittee this morning. Speaking at a House Environment Subcommittee hearing on innovations in agrichemicals, Brian Lutz, PhD, VP agricultural solutions at Corteva, said AI had “revolutionized discovery by allowing us to trade randomness and chance for prediction, specificity and design.”. Predicting the structure of proteins in seconds

FinSMEs
Feb 27th, 2025
Enveda Receives Investment from Sanofi; Brings Total Series C Financing to $150M

Enveda, a Boulder, CO-based biotechnology company empowering life’s chemistry to discover new medicines, received an investment from Sanofi, bringing the total of Series C funding to $150M

Recently Posted Jobs

Sign up to get curated job recommendations

Enveda is Hiring for 3 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →